Abstract

Purpose

This extraordinary woman worked her professional way from a radiation protection engineer to become the successful principal investigator of a prestigious international European project for a new radiation therapy (ERC Synergy grant, HORIZON 2020). The evaluation of the submitted proposal was very positive. The panel proposed that it be funded. Elke tragically passed away a few days before this conclusion of the panel. The present account describes her gradual career development; it includes many episodes that Elke personally chronicled in her curriculum of 2017.

Methods

An internet literature search was performed using Google Scholar and other sources to assist in the writing of this narrative review and account.

Conclusions

In parallel to the development of the new Biomedical Beamline ID17 at the European Synchrotron Radiation Facility in Grenoble in the late nineties, Elke focused her interest and her personal and professional priorities on MRT, particularly on its clinical goals. She outlined her main objectives in several documents: (1) develop a new paradigm of cancer care by broadening the foundation for MRT. (2) Filling the gaps in basic biological knowledge about the mechanisms of MRT effects on normal and neoplastic tissues. (3) Broaden the preclinical level of evidence for the low normal organ toxicity of MRT versus standard X-ray irradiations; preclinical experiments involved the application of MRT to animal tumor patients, to animals of larger size than laboratory rodents, using larger radiation field sizes, and irradiating in a real-time scenario comparable to the one planned for human patients. (4) To foster the specific purpose of radiosurgical MRT of tumor patients at the ESRF that required development of new, specific state of the art modalities and tools for treatment planning, dosimetry, dose calculation, patient positioning and, of particular importance, redundant levels of patient safety. Just as she was about to take responsibility as principal investigator for a prestigious international European project on a new radiation therapy, death called Elke in.

中文翻译：

---

Elke Bräuer-Krisch：奉献、创造力和慷慨：1961 年 5 月 17 日至 2018 年 9 月 10 日

摘要

目的

这位非凡的女性以她的专业方式从一名辐射防护工程师成为著名的国际欧洲新放射治疗项目（ERC Synergy 资助，HORIZON 2020）的成功首席研究员。对提交的提案的评价非常积极。该小组建议为其提供资金。埃尔克在小组讨论结束前几天不幸去世。本叙述描述了她逐渐的职业发展；它包括 Elke 在 2017 年课程中亲自记录的许多情节。

方法

使用谷歌学术和其他资源进行互联网文献搜索，以协助撰写这篇叙述性评论和帐户。

结论

在 90 年代后期在格勒诺布尔的欧洲同步辐射装置开发新的生物医学光束线 ID17 的同时，Elke 将她的兴趣以及她的个人和专业优先事项集中在 MRT 上，特别是其临床目标。她在几份文件中概述了她的主要目标：(1) 通过拓宽 MRT 的基础，开发一种新的癌症治疗范式。(2)填补MRT对正常组织和肿瘤组织作用机制的基础生物学知识空白。(3) 扩大 MRT 与标准 X 射线照射相比正常器官毒性较低的临床前证据水平；临床前实验涉及将 MRT 应用于动物肿瘤患者，比实验室啮齿动物更大的动物，使用更大的辐射场大小，并在与计划用于人类患者的情况相当的实时场景中进行照射。(4) 促进 ESRF 肿瘤患者放射外科 MRT 的特定目的，这需要开发新的、特定的最先进的模式和工具，用于治疗计划、剂量测定、剂量计算、患者定位，特别重要的是冗余水平患者安全。就在她即将担任一项著名的国际欧洲新放射疗法项目的首席研究员时，死亡召唤了埃尔克。特别重要的是，患者安全的冗余级别。就在她即将担任一项著名的国际欧洲新放射疗法项目的首席研究员时，死亡召唤了埃尔克。特别重要的是，患者安全的冗余级别。就在她即将担任一项著名的国际欧洲新放射疗法项目的首席研究员时，死亡召唤了埃尔克。